Literature DB >> 33544136

Monoclonal Antibodies for COVID-19.

Elizabeth C Lloyd1, Tejal N Gandhi1, Lindsay A Petty1.   

Abstract

Entities:  

Year:  2021        PMID： 33544136     DOI： 10.1001/jama.2021.1225

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  11 in total

Review 1.  Efficacy of COVID-19 treatments among geriatric patients: a systematic review.

Authors:  Helen Senderovich; Danusha Vinoraj; Madeline Stever; Sarah Waicus
Journal:  Ther Adv Infect Dis       Date:  2022-06-01

2.  Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals.

Authors:  Faith C Quenzer; Andrew T Lafree; Londyn Grey; Sukhdeep Singh; Cameron Smyers; Bruce Balog; Henry Montilla Guedez; Kaitlin McIntyre; Sharon Wulfovich; Juli Ramirez; Talia Saikhon; Christian Tomaszewski
Journal:  West J Emerg Med       Date:  2022-03-17

3.  Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies.

Authors:  Puneet Rawat; Divya Sharma; Ambuj Srivastava; Vani Janakiraman; M Michael Gromiha
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

Review 4.  Therapeutic strategies to fight COVID-19: Which is the status artis?

Authors:  Cristina Scavone; Annamaria Mascolo; Concetta Rafaniello; Liberata Sportiello; Ugo Trama; Alice Zoccoli; Francesca Futura Bernardi; Giorgio Racagni; Liberato Berrino; Giuseppe Castaldo; Enrico Coscioni; Francesco Rossi; Annalisa Capuano
Journal:  Br J Pharmacol       Date:  2021-05-07       Impact factor: 9.473

5.  Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein.

Authors:  Anton Shuster; Dany Pechalrieu; Cody B Jackson; Daniel Abegg; Hyeryun Choe; Alexander Adibekian
Journal:  ACS Chem Biol       Date:  2021-11-18       Impact factor: 5.100

Review 6.  Ofeleein i mi Vlaptin-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.

Authors:  Jannis Kountouras; Dimitra Gialamprinou; Georgios Kotronis; Apostolis Papaefthymiou; Eleftheria Economidou; Elpidoforos S Soteriades; Elisabeth Vardaka; Dimitrios Chatzopoulos; Maria Tzitiridou-Chatzopoulou; Dimitrios David Papazoglou; Michael Doulberis
Journal:  Medicina (Kaunas)       Date:  2022-02-17       Impact factor: 2.430

7.  SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy.

Authors:  Ziwei Yang; Yang Han; Shilei Ding; Wei Shi; Tongqing Zhou; Andrés Finzi; Peter D Kwong; Walther Mothes; Maolin Lu
Journal:  mBio       Date:  2022-02-15       Impact factor: 7.867

Review 8.  Severe Acute Respiratory Syndrome Type 2-Causing Coronavirus: Variants and Preventive Strategies.

Authors:  Mehmet Onur Aydogdu; Jennifer L Rohn; Nazila V Jafari; Francis Brako; Shervanthi Homer-Vanniasinkam; Mohan Edirisinghe
Journal:  Adv Sci (Weinh)       Date:  2022-01-17       Impact factor: 16.806

Review 9.  Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.

Authors:  Divya Narayanan; Tanyalak Parimon
Journal:  Int J Mol Sci       Date:  2022-07-12       Impact factor: 6.208

Review 10.  Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?

Authors:  Patricia Rieken Macêdo Rocco; Bruno Solano de Freitas Souza; Kátia Nunes da Silva; André Luiz Nunes Gobatto; Zaquer Suzana Munhoz Costa-Ferro; Bruno Raphael Ribeiro Cavalcante; Alex Cleber Improta Caria; Luciana Souza de Aragão França; Carolina Kymie Vasques Nonaka; Fernanda de Macêdo Lima; Miquéias Lopes-Pacheco
Journal:  Stem Cell Res Ther       Date:  2021-07-27       Impact factor: 6.832
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.